Research Article | | Peer-Reviewed

The Effect of Multiple Glycemic Parameters on Mortality and Clinical Outcomes in Critically Ill Patients in Intensive Care Unit

Received: 18 March 2025     Accepted: 31 March 2025     Published: 22 April 2025
Views:       Downloads:
Abstract

Background: Dysglycemia is frequently encountered in the ICU and it includes hyperglycemia, hypoglycemia and glycemic variability which are associated with increased rate of mortality and morbidity. Hyperglycemia is the most frequent among the components of dysglycemia and its prevalence is 40-90%. The prevalence and outcome of multiple glycemic parameters in the ICU has not been described in Ethiopia. Objectives: The aim of the study is to describe the effect of multiple glycemic parameters on intensive care unit mortality and clinical outcomes in selected tertiary hospitals. Methods: An institution based cross-sectional study was conducted by using systematic random sampling. Data was collected from patient cards and was entered using Epi Info 7.2. Data analysis was done using SPSS 27.0. Descriptive statistics was used to summarize the data. Associations between variables were measured with chi square and Mann Whitney U test. Multivariable logistic regression was used to identify predictors of mortality and test the association of multiple glycemic parameters and mortality. Odds ratios with 95% confidence intervals were calculated, and a p-value <0.05 was considered to declare significance Result: The study included 392 patient records, with a median age of 38 years [IQR 28 – 56]. About 53% of patients were females. The prevalence of hyperglycemia, hypoglycemia and high glycemic variability was 90.3%, 16.3% and 19.4% respectively. Hypoglycemia was significantly associated with mortality (AOR 2.98, p < .05). Patients with hyperglycemia and hypoglycemia had significantly longer lengths of stay and durations of mechanical ventilation. High glycemic variability was not significantly associated with mortality, length of stay or duration of mechanical ventilation. Conclusion: Dysglycemia is very prevalent among patients admitted in the ICU and hypoglycemia may be associated with ICU mortality and adverse clinical outcomes.

Published in International Journal of Diabetes and Endocrinology (Volume 10, Issue 2)
DOI 10.11648/j.ijde.20251002.11
Page(s) 26-36
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2025. Published by Science Publishing Group

Keywords

Critical Illness, Dysglycemia, Stress Hyperglycemia, Hypoglycemia, Glycemic Variability, Mortality

1. Introduction
An intensive care unit (ICU) is a specialized unit of a hospital reserved for patients with serious and life-threatening illnesses that call for careful monitoring, specialized care, and the use of various high-technology equipment and medications to preserve normal physiologic function in humans. ICUs are advanced facilities with the most cutting-edge medical equipment and trained staff in the majority of developed nations. Caring for the critically ill patients is a challenge in developing countries, where health needs often outstrip available resources .
Critically ill patients frequently have stress hyperglycemia (also called critical illness hyperglycemia). It is reported prevalence in ICU ranges from 40% to 90% depending on the cut-off value used . The American diabetic association (ADA) defines in-hospital hyperglycemia as any blood glucose (BG) value above 140 mg/dl . Although the primary etiology of stress hyperglycemia is the acute metabolic and hormonal changes associated with the response to injury and stress, there are several factors that can cause hyperglycemia in these groups of patients. Some of the causes include use of vasopressors and glucocorticoids. While it is known that patients with known diabetes are at risk for developing hyperglycemia while critically ill, people who have never been diagnosed with diabetes are actually the ones who are most at risk . Poor outcomes like mortality and increased length of ICU & hospital stay are associated with stress hyperglycemia. Although whether hyperglycemia is a cause of increased hospital mortality or just an epiphenomenon was an issue of controversy, there are several studies that have shown the association was independent of disease severity .
Hospitalized individuals with hyperglycemia fall into three categories . Patients with known history of diabetes, patients with unrecognized diabetes and patients with stress hyperglycemia. Unrecognized diabetes and stress hyperglycemia are differentiated using hemoglobin A1c (HbA1c). If the patient’s HbA1c is less than 6.5%, the patient has a stress hyperglycemia. But if the patient’s HbA1c is 6.5% or more, the patient has unrecognized diabetes .
Hypoglycemia is defined as having one or more BG values less than 70 mg/dL according to ADA. This value is recognized as a threshold for neuroendocrine responses to falling glucose in people without diabetes A blood glucose concentration <54 mg/dL is the threshold at which neuroglycopenic symptoms begin to occur . Although the severity of hypoglycemia may be just a marker of the severity of illness, hypoglycemia itself might be harmful for acutely ill patients. For example, hypoglycemia might be biologically toxic by inducing neuroglycopenia, increasing the systemic inflammatory response, causing cerebral vasodilatation, impairing sympathetic nervous system responsiveness, inhibiting the corticosteroid response to stress, or by mechanisms that have yet to be determined .
Dysglycemia is defined by hyperglycemia, hypoglycemia and high glycemic variability & is associated with poor outcomes. Previously the focus of glycemia in critically ill patients was on controlling hyperglycemia and hypoglycemia, but recently glycemic variability (GV) has entered the picture as one the factors that affects outcomes in this group of patients .
Glycemic variability refers to swings in blood glucose levels. Best methods to measure GV are standard deviation (SD) and coefficient of variance (CV). Although the underlying mechanisms are not completely understood, increasing evidence indicates that fluctuations in blood glucose are associated with factors associated with the pathogenesis of vascular damage like endothelial dysfunction, inflammation and oxidative stress. By these proposed mechanisms high GV contributes to morbidity and mortality of critically ill patients .
Determining the patterns of dysglycemia and associated clinical outcomes in critically ill patients would help develop the necessary attitude towards the problem among physicians. Identifying which patients are at high risk for dysglycemia associated morbidity and mortality will help clinicians by guiding their decision-making process. Factors associated with prolonged length of stay and mortality in the ICU are also crucial in developing quality improvement initiatives targeting critically ill patients. The findings of this study can be of valuable input for health care authorities in understanding, prioritizing and planning glycemic control related problems and developing the capacity to mitigate the impacts of morbidity and mortality of critically ill patients. The magnitude and impacts of this problem can serve as possible evidence for the proper allocation of resources in critical care settings. The findings of this study can also emphasize the need for adopting clinical management guidelines for optimizing glycemic control of critically ill patients in the ICU. This study will be one of the first in exploring glycemic control problems among critically ill patients in our country. Apart from promoting evidence-based practice, this study can also serve as a baseline for conducting further studies in this area.
2. Materials and Methods
A hospital based cross-sectional study was conducted in St Paul’s hospital millennium medical college (SPHMMC) and Tikur Anbessa Specialized Hospital (TASH) in Addis Ababa, Ethiopia. SPHMMC and TASH are the two largest tertiary hospitals in the country. SPHMMC has more than 700 beds, The College sees an average of 1200 emergency and outpatient clients daily . TASH has a total bed capacity of approximately 800 beds and provides specialty services for nearly half a million patients per year coming from every corner of the country. The ICU setup of SPHMMC has 2 separate ICUs and 14 beds. According to data reported from the hospital's HMIS office the ICU has an average monthly admission of 26 patients and an average yearly admission of 312 patients. The ICU setup of TASH has a total of 12 beds. About 180–200 patients receive invasive mechanical ventilation per year in the intensive care unit .
Selected critically ill adult (≥18 years of age) patients admitted to SPHMMC and TASH intensive care units from April 1, 2022 to March 31, 2023 were included in the study. Patients with the diagnosis of Diabetic Ketoacidosis or Hyperglycemic Hyperosmolar Syndrome on ICU admission and patients known to be pregnant or lactating were excluded from the study. A total of 813 patient records were screened for inclusion, out of which 397 had incomplete data, and 42 were excluded based on predefined exclusion criteria. 392 patient records were included in the final analysis.
Data was collected from patients’ cards and ICU follow up sheets using a data collection checklist. Blood glucose measurements was grouped and GV was reported as coefficient of variance calculated from each measurement. High glycemic variability was defined as coefficient of variance of greater than 36% calculated from the patient’s total blood glucose measurements .
Blood glucose measurements were grouped into 5 using 4 cutoff values per ADA guidelines. The first was 54 mg/dL which defines level 2 hypoglycemia. The second was 70 mg/dL which defines hypoglycemia. The third was 140 mg/dL which defines in-hospital hyperglycemia. The fourth was 180 mg/dL which defines uncontrolled hyperglycemia and is the upper limit of the glycemic target in the ICU .
Age-combined Charlson comorbidity index (CCI) was used as a representation of patients’ comorbidities . Noradrenaline equivalent doses were used to calculate cumulative doses of vasopressors . Hydrocortisone equivalent doses were used to calculate cumulative doses of steroids .
Data entry was done using Epi Info version 7.2 and exported to Statistical Package for the Social Sciences (SPSS) version 27.0 for further data analysis. Descriptive analysis was carried out for all variables. Categorical variables were recorded as percentages and frequency and were compared by chi square test. Continuous variables were recorded as median and interquartile range and were compared by Mann Whitney U test. Bivariate analysis between dependent and independent variables was performed using binary logistic regression. Multivariate logistic regression was used to identify predictors of mortality and test the association of glycemic parameters and mortality. Mann Whitney U was used to assess the relation between multiple glycemic parameters and increased ICU length of stay and increased duration on MV. If the p value was <0.05, then the difference between various parameters was considered statistically significant. Results were presented as tables, graphs and charts.
3. Results
3.1. Demographic Characteristics
The median [IQR] age of patients included in this study is 38 years [IQR = 28 – 56] and the age group 18 to 40 years constitute 55.6% (218) of the sample. The sex distribution was 47.4% (186) females and 52.6% (206) males. The permanent area of residence for 62.84% (246) of patients is Addis Ababa, followed by Oromia (24.5% (96)) and Amhara (4.6% ) regions. (Table 1).
Table 1. Demographic characteristics of the sample.

Characteristics

Overall

ICU Mortality

p value

Dead

Alive

Study Participants

392 (100.0)

138 (35.2)

254 (64.8)

NA

Age, M (IQR)

38 (28 - 56)

38 (28 - 54)

38 (30 - 56)

.653

Age Group (yrs.)

18–30

124 (31.6)

42 (33.9)

82 (66.1)

.008

31–40

94 (24.0)

30 (31.9)

64 (68.1)

41-50

54 (13.8)

28 (51.9)

26 (48.1)

51-60

44 (11.2)

14 (31.8)

30 (68.2)

61-70

48 (12.2)

10 (20.8)

38 (79.2)

71-80

20 (5.1)

8 (40.0)

12 (60.0)

> 80

8 (2.0)

6 (75.0)

2 (25.0)

Sex

Female

186 (47.4)

72 (38.7)

114 (61.3)

.161

Male

206 (52.6)

66 (32.0)

140 (68.0)

Address

Addis Ababa (city)

246 (62.8)

90 (36.6)

156 (63.4)

.01

Afar Region

2 (0.5)

0 (0.0)

2 (100.0)

Amhara Region

18 (4.6)

12 (66.7)

6 (33.3)

Oromia Region

96 (24.5)

24 (25.0)

72 (75.0)

Southern Nations, Nationalities and Peoples

16 (4.1)

6 (37.5)

10 (62.5)

Tigray Region

8 (2.0)

4 (50.0)

4 (50.0)

Others

6 (1.5)

2 (33.3)

4 (66.7)

*p values are for Pearson’s Chi-square test of independence.
3.2. Clinical Characteristics
The most common comorbidities were hypertension (22.40% (88)), Chronic Heart Failure (12.8% (50)), HIV infection (10.2% (40)), Type 2 Diabetes Mellitus (9.7%% (38)), chronic kidney disease (9.2% (36)) and malignancies (6.1% (24)). The median age-combined CCI is 1 with IQR of 0-4 and 32.1% (126) of patients had an age-combined CCI score of 0. The commonest diagnosis made at or during the admission are hospital acquired infection (39.3% (154)), acute kidney injury (37.8% (148)), respiratory failure (26.5% (104)), shock (19.9% (78)), acute heart failure (10.2% (40)), and acute cerebral accidents (7.1% (28)). (Table 2).
Table 2. Diagnosis made during ICU admission and mortality.

Characteristics

Overall

ICU Mortality

p value*

Dead

Alive

Study Participants

392 (100.0)

138 (35.2)

254 (64.8)

NA

Acute Kidney Injury

148 (37.8)

64 (43.2)

84 (56.8)

.012

Acute Myocardial Infarction

8 (2.0)

2 (25.0)

6 (75.0)

.718

Acute Heart Failure

40 (10.2)

12 (30.0)

28 (70.0)

.601

Acute Cerebral accident

28 (7.1)

4 (14.3)

24 (85.7)

.022

Hospital Acquired Infections

154 (39.3)

60 (39.0)

94 (61.0)

.234

CNS Infections**

10 (2.6)

4 (40.0)

6 (60.0)

.746

Shock

78 (19.9)

44 (56.4)

34 (43.6)

<.001

Type of shock

No Shock

314 (80.1)

94 (29.9)

220 (70.1)

<.001

Septic Shock

56 (14.3)

38 (67.9)

18 (32.1)

Hypovolemic Shock

4 (1.0)

0 (0.0)

4 (100.0)

Cardiogenic Shock

18 (4.6)

6 (33.3)

12 (66.7)

Respiratory Failure

104 (26.5)

60 (57.7)

44 (42.3)

<.001

Acute Liver Failure

16 (4.1)

10 (62.5)

6 (37.5)

.03

Tuberculosis

22 (5.6)

12 (54.5)

10 (45.5)

.065

Venous thromboembolism

18 (4.6)

6 (33.3)

12 (66.7)

.865

Others

100 (25.5)

10 (10.0)

90 (90.0)

<.001

*p values are for Pearson’s chi square test.

** CNS – Central nervous system.

Figure 1. Age-combined CCI and ICU mortality.
3.3. Glycemic Parameters
The estimated prevalence of hyperglycemia in the sample was 90.3% (95% CI [86.9%, 92.9%]). The prevalence of hypoglycemia was 16.3% (95% CI [13%, 20.3%]) and the prevalence of high glucose variability was estimated to be 19.4 (95% CI [15.8%, 23.6%]). The Prevalence of hyperglycemia in non-diabetics was 89.6% (95% CI [56.9%, 92.4%]). Because of the limitation associated with the small subset of patients with HbA1C determined within the preceding 3 months (9.3%, 34) and even smaller number of patients who were not diabetic (29.4%, 10) the prevalence of stress hyperglycemia cannot be concluded.
Table 3. Glycemic Profiles, administered medications, age-combined CCI and ICU Mortality.

Characteristics

Overall

ICU Mortality

p value*

Dead

Alive

Age-combined CCI, M (IQR)

1 (0 - 4)

2 (0 - 6)

1 (0 - 3)

.001

Glycemic Profiles

Stress Hyperglycemia

8 (2.0)

0 (0.0)

8 (100.0)

.055

Hyperglycemia

354 (90.3)

122 (34.5)

232 (65.5)

.371

Hypoglycemia

64 (16.3)

38 (59.4)

26 (40.6)

<.001

High Glycemic Variability

76 (19.4)

32 (42.1)

44 (57.9)

.161

Glycemic variability, M (IQR)

26.1 (19.8 - 32.7)

27.21 (21.2 - 35.6)

24.7 (19.1 - 30.5)

.009

Medications given in the ICU

Use of insulin

66 (16.8)

16 (24.2)

50 (75.8)

.048

Mode of insulin

None

326 (83.2)

122 (37.4)

204 (62.6)

.065

Subcutaneous

56 (14.3)

12 (21.4)

44 (78.6)

Intravenous

10 (2.6)

4 (40.0)

6 (60.0)

Use of any glucocorticoids

78 (19.9)

42 (53.8)

36 (46.2)

<.001

Use of any Vasopressors

122 (31.1)

86 (70.5)

36 (29.5)

<.001

Dose of Steroids. (mg), M (IQR) **

800 (360 - 1280)

640 (250 - 853)

1085 (640 - 1800)

.001

Dose of Vasopressors (mg), M (IQR) ***

42.6 (5 - 93)

52 (10 - 166)

15 (5 - 53)

.002

Dose of Insulin, M (IQR)

60 (19 – 210)

146.5 (13.5 - 225.5)

49 (19 - 187)

.719

Abbreviations: CCI – Charlson Comorbidity Index, ICU – Intensive Care Unit, M (IQR) – Median (interquartile range).

*p values are for Pearson’s Chi-square test of independence, except: Mann-Whitney U test for Doses of Steroid, vasopressor, insulin, glycemic variability, and age-combined CCI.

** Dose of steroids are in hydrocortisone equivalent doses.

*** Doses of vasopressors are in noradrenaline equivalent doses.

3.4. Associations of Glycemic Parameters and ICU Mortality
The overall prevalence ICU mortality in our study was 35.2% (95% CI [30.6%, 40.1%]). Chi-square test of independence was performed to examine the relation between categorical independent variables and ICU mortality. The result revealed that age group, acute kidney injury, acute cerebral accidents, Shock, Respiratory failure, Acute liver failure, Hypoglycemia, Use of insulin, Use of glucocorticoids, and Use of vasopressor were significantly associated with mortality (p < 0.05).
Crude associations for all independent variables with ICU mortality was done by using bivariable logistic regression. Variables with p values of less than 0.2 in the bivariate logistic regression analysis were selected for multivariable logistic regression analysis. Subsequently age groups, age-combined CCI, acute kidney injury, acute cerebral accidents, shock, respiratory failure, acute liver failure, hypoglycemia, glycemic variability, use of insulin, use of vasopressors, and use of glucocorticoids were candidates for the final model. After adjusting for potential confounders only age-combined CCI, respiratory failure, hypoglycemia, use of insulin and use of vasopressors were significantly associated with ICU mortality among the study population.
The logistic regression analysis revealed that hypoglycemia had a significant positive effect on the likelihood of mortality. The odds ratio for hypoglycemia was 2.98, indicating that for every one record of hypoglycemia ICU patients have 3-fold increased odds of dying in reference to patients with no hypoglycemia. After controlling for age groups, diagnoses made during the ICU stay, Shock, glycemic variability, age combined CCI, use of insulin, use of glucocorticoids, and use of vasopressors, the relationship between hypoglycemia and mortality remained statistically significant. (B = 1.10, SE = 0.41, Wald χ²(df) = 7.18 (1), p <.05, AOR = 2.98, 95% CI [1.34, 6.62]).
The logistic regression analysis also revealed a statistically significant association between insulin use and mortality (B = -1.64, SE = 0.464, Wald = 12.474, df = 1, p < 0.001). Patients who used insulin had a lower likelihood of mortality compared to those who did not use insulin. A Spearman’s correlation was conducted to evaluate the relationship between hyperglycemia and BG between 140-180 mg/dL with dose of insulin. There was a significant positive relationship between hyperglycemia and dose of insulin, (rs = 0.379, p = <.001) and there was a significant positive relationship between BG between 140-180 mg/dL and dose of insulin, (rs = 0.168, p = <0.001).
Table 4. Multivariable Binary Logistic Regression analysis of 392 patients for predictors of ICU mortality.

Parameter

COR (95%CI)

AOR (95%CI)

p value

Age Groups (years)

18–30

1

1

31–40

0.92 (0.52, 1.62)

0.79 (0.39, 1.62)

0.515

41-50

2.103 (1.10, 4.03)

2.31 (0.95, 5.64)

0.066

51-60

0.91 (0.44, 1.90)

0.64 (0.22, 1.85)

0.408

61-70

0.51 (0.23, 1.13)

0.17 (0.05, 0.54)

0.003

71-80

1.30 (0.49, 3.43)

1.24 (0.33, 4.63)

0.747

> 80

5.86 (1.13, 30.28)

1.09 (0.14, 8.29)

0.935

Age-combined CCI

1.17 (1.08, 1.27)

1.30 (1.14, 1.47)

<0.001

Acute Kidney Injury

1.75 (1.14, 2.68)

1.15 (0.62, 2.11)

0.658

Acute Cerebral Accident

0.286 (0.1, 0.84)

0.86 (0.24, 3.16)

0.825

Shock

3.029 (1.821, 5.04)

0.48 (0.20, 1.15)

0.101

Respiratory Failure

3.67 (2.30, 5.86)

4.84 (2.47, 9.48)

<0.001

Acute Liver Failure

3.23 (1.15, 9.09)

0.68 (0.17, 2.75)

0.585

Hypoglycemia

3.33 (1.92, 5.78)

2.98 (1.34, 6.62)

0.007

Glycemic variability

1.02 (1.00, 1.04)

1.00 (0.98, 1.03)

0.798

Use of insulin

0.54 (0.29, 0.98)

0.19 (0.08, 0.48)

<0.001

Use of glucocorticoids

2.65 (1.60, 4.39)

1.19 (0.58, 2.42)

0.642

Use of vasopressors

10.02 (6.12, 16.40)

13.67 (6.39, 29.23)

<0.001

Only variables with p value <0.2 in the bivariable regression are depicted here; 1: Reference category.
3.5. Length of Stay and Duration of Mechanical Ventilation
A Mann-Whitney U test was performed to evaluate whether Length of stay and duration of MV differed by hyperglycemia, hypoglycemia and high GV. The results indicated that patients with hyperglycemia and hypoglycemia had significantly longer LOS than patients without hyperglycemia and hypoglycemia respectively, (z = -4.83, p = <0.001 & z = -2.83, p=0.005 respectively). There was no significant difference between the LOS of patients with high GV and normal GV, (z= -0.64, p= 0.53). Similarly, patients with hyperglycemia and hypoglycemia also had significantly longer duration of MV than patients without hyperglycemia and hypoglycemia respectively, (z = -2.07, p = 0.04 & z = -4.46, p= <0.001 respectively). And there was no significant difference between the duration of MV of patients with high GV and normal GV, (z= -0.53, p= 0.60).
Table 5. Glycemic profiles and Length of stay in the ICU.

Glycemic profiles

Count

Length of stay (Days)

Mean

Median

IQR

p value

Hyperglycemia

No

38

3.32

2

1-4

<0.001

Yes

354

8.15

6

3-9

Hypoglycemia

No

328

7.05

5

3-8

0.005

Yes

64

10.91

6.5

3.5-13.5

High GV

No

316

7.91

5

3-9

0.53

Yes

76

6.74

4.5

3-8

Table 6. Glycemic profiles and duration of MV.

Glycemic profiles

Count

Duration of MV (Days)

Mean

Median

IQR

p value

Hyperglycemia

No

38

1.11

0

0-2

0.04

Yes

354

3.44

1

0-5

Hypoglycemia

No

328

2.49

0

0-3

<0.001

Yes

64

6.88

3

0-7

High GV

No

316

3.27

1

0-4

0.60

Yes

76

2.97

1.5

0-4

4. Discussion
Our study aimed to determine the effect of multiple glycemic parameters on ICU mortality and clinical outcomes in critically ill patients. The prevalence of hyperglycemia in the sample was 90.3% which is in line with the prevalence of 40-90% which is reported worldwide by different studies, and higher than the studies done in Egypt . It is worth noting that there are significant inconsistencies between the cutoff blood glucose used by the different studies mentioned in this paper. The prevalence of hypoglycemia was 16.3% which is higher than the 5% prevalence reported in the retrospective analysis of 52,107 ICU patients done in Hong Kong and lower than the 37% prevalence reported from a multicentric study from Netherlands and USA . The prevalence of high glucose variability was estimated to be 19.4%.
From the markers of dysglycemia, hyperglycemia, hypoglycemia and high glycemic variability, only hypoglycemia has a significant independent association with mortality. This finding was also demonstrated in an observational study done in Australia which showed higher mortality of hypoglycemia as compared to normoglycemia . Patients with hypoglycemia also had significantly longer LOS and longer duration of MV. An increased length of stay was also associated with hypoglycemia in a review of 6240 critically ill patients, and the more the number of hypoglycemic events, the longer the length of stay. Independent of the severity of the disease, even a single episode of hypoglycemia (70 mg/dL) led to a significantly longer length of stay . This association was also reflected in our study. In contrast to our findings of longer MV duration in hypoglycemic patients, a recent study done in Brazil in 542 ICU patients found out hypoglycemia was independently associated with increased mortality and increased need of MV but shorter duration of ICU and hospital length of stay, and shorter duration of MV . But this Brazilian study of assessed hypoglycemia within the first 24 hours of ICU admission, and the association with shorter duration of stay was controlling disease severity for SAPS 3 (Simplified Acute Physiology III) score, which was one of the main limitations of our study.
Our study did not show that hyperglycemia had a significant association with mortality, but it did show patients with hyperglycemia had increased LOS and duration of mechanical ventilation. The association between hyperglycemia and mortality varied in different literatures. A retrospective cohort study including 259,040 ICU admissions found that increasing severity of hyperglycemia was associated with increased mortality. However, a more recent meta-analysis which included 18,098 patients from 35 studies across the spectrum of adult critical care did not find significant differences in hospital mortality between four glycemic control categories (<110 mg/dl, 110-144 mg/dl, 144-180 mg/dl and >180 mg/dL) . The Brazilian study mentioned above also found that one of the poor outcomes associated with stress hyperglycemia, especially within the first 24hrs after ICU admission was increased need for MV similar to our finding of significantly longer duration of mechanical ventilation in patients with hyperglycemia .
High GV in contrast did not have a significant effect on mortality, LOS and duration of MV. A Prospective Observational Study done in India found there was a significant in hospital and ICU mortality which is associated with increasing levels of GV, measured by CV, which our study did not reproduce. Although they used different measurements for GV, the study done in Brazil showed a statistically significant association between high GV between mortality, ICU LOS and duration of mechanical ventilation .
Our logistic regression analysis also revealed a statistically significant association between insulin use and mortality. Patients who used insulin had a lower likelihood of mortality compared to those who did not use insulin. There was a significant positive relationship between hyperglycemia and dose of insulin indicating higher frequency hyperglycemia was associated with the requirement of higher doses of insulin. There was a significant positive relationship between BG between 140-180 mg/dL and dose of insulin but there was no statistically significant relationship between hypoglycemia and dose of insulin. This suggests patients who were being treated with insulin were not developing hypoglycemia and were achieving within target BG. So, in our study the benefit that patients on insulin therapy drew regarding the mortality benefit is potentially from the achieving within target BG.
The positive relationships between hyperglycemia, the dose of insulin and frequency of within target blood glucose levels underscore the need for vigilant glycemic management to achieve target glucose levels. These findings contribute to the existing literature on emphasizing the potential benefits of insulin therapy in critically ill patients targeting blood glucose levels between 140-180 mg/dL, while avoiding hypoglycemia. This is in keeping with the finding of the NICE-SUGAR trial and recommendations of the American diabetic association .
The other key finding of our study is age-combined CCI, respiratory failure, use of vasopressors and hypoglycemia, as mentioned above, were independent predictors of mortality. The absence of established scoring systems for severity of illness like APACHE, SOFA, or SAPS3 may limit the ability to fully understand the impact of illness severity on mortality outcomes in our study population. The predictors identified in our study could be confounded by the severity of illness. However, a study done at Hawassa University Comprehensive Specialized Hospital demonstrated that the mere requirement of mechanical ventilation and presence of shock during admission were independent predictors of ICU mortality .
5. Conclusion
Dysglycemia, i.e. hypoglycemia, hyperglycemia, and high glycemic variability, is very prevalent among patients admitted in the ICU and it is potentially associated with adverse outcomes. Hypoglycemia was associated with significantly longer ICU LOS, longer duration of MV, and higher mortality. Similarly, hyperglycemia was associated with longer ICU LOS and longer duration of MV, but not with higher mortality. There was no strong impact of high glycemic variability on ICU LOS, duration of MV, or mortality. Achieving target blood glucose levels of 140–180 mg/dL in critically ill patients may be advantageous, as suggested by the association between the use of insulin and lower mortality rates. Further research to explore the impact of glycemic control on clinical outcomes in patients admitted to the ICU considering and incorporating severity of illness scores is required.
Abbreviations

ADA

American Diabetic Association

AOR

Adjusted Odds Ratio

APACHE

Acute Physiology and Chronic Health Evaluation

BG

Blood Glucose

CCI

Charlson Comorbidity Index

CRP

C-reactive Protein

CV

coefficient of Variance

DM

Diabetes Mellitus

GV

Glycemic Variability

HbA1c

Glycohemoglobin, Hemoglobin A1c

HMIS

Health Management Information System

ICU

Intensive Care Unit

IQR

Interquartile Range

LOS

Length of Stay

MV

Mechanical Ventilator

OR

Odds Ratio

SD

Standard Deviation

SAPS3

Simplified Acute Physiology III

SOFA

Sequential Organ Failure Assessment

SPHMMC

St. Paul’s Hospital Millennium Medical College

TASH

Tikur Anbessa Specialized Hospital

VTE

Venous Thromboembolism

Acknowledgments
We would like to thank SPHMMC and TASH Department of internal medicine for giving us the opportunity to conduct this study. Last but not the least, we would like to extend our gratitude toward those authors and researchers of articles for their valuable work we have read and cited.
Author Contributions
Wasihun Zerfu Zewde: Conceptualization, Methodology, Formal analysis, Writing—original draft. Writing—review and editing, Project administration
Amare Gulilat Mamo: Supervision, Validation, Methodology
Helina Yohannes Afework: Data curation, Investigation
Mahlet Mitiku Desalegn: Software, Resources
Ermiyas Berehanu Hayle: Visualization, Methodology
Zewdu Abadi Tsegay: Writing – review & editing
Mehariw Wondim Netsere: Writing – review & editing, Resources
Amir Muhidin Abrahim: Softwares, Data curation
Yeabtsega Amlaku Asres: Data curation, Investigation
Funding
This work is supported by St. Paul’s Hospital Millennium Medical College for partial fulfillment of the requirement of specialty certificate in Internal Medicine.
Data Availability Statement
The data is available from the corresponding author upon reasonable request.
Conflicts of Interest
The authors declare no conflicts of interest.
References
[1] Wotiye AB, Shimber ET, Ayele BA. Factors Associated with ICU Mortality at Hawassa University Comprehensive Specialized Hospital (HUCSH). Ethiop J Health Sci. 2022 May 1; 32(3): 505.
[2] Mamtani M, Kulkarni H, Bihari S, Prakash S, Chavan S, Huckson S, et al. Degree of hyperglycemia independently associates with hospital mortality and length of stay in critically ill, nondiabetic patients: Results from the ANZICS CORE binational registry. J Crit Care. 2020 Feb 1; 55: 149–56.
[3] ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2023. Diabetes Care. 2023 Jan 1; 46(Supplement_1): S267–78.
[4] Ellahham S. Insulin therapy in critically ill patients. Vol. 6, Vascular Health and Risk Management. 2010. p. 1089–101.
[5] Krinsley JS. Glycemic variability: A strong independent predictor of mortality in critically ill patients. Crit Care Med. 2008; 36(11): 3008–13.
[6] Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: An Independent Marker of In-Hospital Mortality in Patients with Undiagnosed Diabetes. J Clin Endocrinol Metab. 2002 Mar 1; 87(3): 978–82.
[7] Mifsud S, Schembri EL, Gruppetta M. Stress-induced hyperglycaemia. Br J Hosp Med. 2018 Nov 2; 79(11): 634–9.
[8] Egi M, Furushima N, Makino S, Mizobuchi S. Glycemic control in acute illness. Vol. 70, Korean Journal of Anesthesiology. Korean Society of Anesthesiologists; 2017. p. 591–5.
[9] Zhou Z, Sun B, Huang S, Zhu C, Bian M. Glycemic variability: adverse clinical outcomes and how to improve it? Vol. 19, Cardiovascular Diabetology. BioMed Central; 2020.
[10] Hermanides J, Vriesendorp TM, Bosman RJ, Zandstra DF, Hoekstra JB, Devries JH. Glucose variability is associated with intensive care unit mortality. Crit Care Med. 2010; 38(3): 838–42.
[11] About – Saint Paul’s Millennium Medical College. Available from:
[12] Tsegay K, Teklu T, Debebe F, Beza L. Outcomes of Patients on Mechanical Ventilation among Adult Intensive Care Units of Tikur Anbesa Specialized Hospital, Addis Ababa, Ethiopia. 2023.
[13] Brunner R, Adelsmayr G, Herkner H, Madl C, Holzinger U. Glycemic variability and glucose complexity in critically ill patients: a retrospective analysis of continuous glucose monitoring data. 2012.
[14] Charlson ME, Pompei P, Ales KL, MacKenzie CR: A New Method of Classifying Prognostic Comorbidity in Longitudinal Studies: Development and Validation. Journal of Chronic Diseases 40: 373-383, 1987.
[15] Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM, Sundararajan V. Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 Countries. Am. J. Epidemiol. (2011).
[16] Radovanovic D, Seifert B, Urban P, Eberli FR, Rickli H, Bertel O, Puhan MA, Erne P; AMIS Plus Investigators. Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome. Insights from the nationwide AMIS Plus registry 2002-2012. Heart. 2014 Feb; 100(4): 288-94.
[17] Kotani, Y., Di Gioia, A., Landoni, G., Belletti, A., & Khanna, A. K. (2023). An updated “norepinephrine equivalent” score in intensive care as a marker of shock severity. Critical Care, 27(1).
[18] Meikle AW and Tyler FH. Potency and duration of action of glucocorticoids. Am J of Med 1977; 63; 200. (456).
[19] Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005; 44(1): 61-98.
[20] Temel Ş, Yüksel RC, Gündoğan K, Ülgey A, Güven M, Sungur M. Stress hyperglycemia incidence in critically ill patients: Cross-sectional observational study. Journal of Medical and Surgical Intensive Care Medicine. 2018 Aug 1; 9(2): 46–50.
[21] Khalil U, Ghoniem M, Khalil OA, Yuossef MM, Sherif MM, Alnahall A. Epidemiology and clinical outcome of ICU-acquired Stress hyperglycemia in Critically ill Medical patients (Single center study). Vol. 9, J Am Sci. 2013.
[22] Stoudt K, Chawla S. Don’t Sugar Coat It: Glycemic Control in the Intensive Care Unit. Vol. 34, Journal of Intensive Care Medicine. SAGE Publications Inc.; 2019. p. 889–96.
[23] Krinsley J, Schultz MJ, Spronk PE, van Braam Houckgeest F, van der Sluijs JP, Mélot C, et al. Mild hypoglycemia is strongly associated with increased intensive care unit length of stay. Ann Intensive Care. 2011 Dec; 1(1).
[24] Fong KM, Au SY, Ng GWY. Glycemic control in critically ill patients with or without diabetes. BMC Anesthesiol. 2022 Dec 1; 22(1): 1–11.
[25] Egi M, Bellomo R, Stachowski E, French CJ, Hart GK, Taori G, et al. Hypoglycemia and outcome in critically ill patients. Mayo Clin Proc. 2010; 85(3): 217–24.
[26] Bellaver P, Schaeffer AF, Dullius DP, Viana M v., Leitão CB, Rech TH. Association of multiple glycemic parameters at intensive care unit admission with mortality and clinical outcomes in critically ill patients. Sci Rep. 2019 Dec 1; 9(1).
[27] Yatabe, T., Inoue, S., Sakaguchi, M. et al. The optimal target for acute glycemic control in critically ill patients: a network meta-analysis. Intensive Care Med 43, 16–28 (2017).
[28] Standards of Care in Diabetes-2023. 2022; Available from:
[29] The NICE-SUGAR study investigators. Intensive versus Conventional Glucose Control in Critically Ill Patients. New England Journal of Medicine. 2009 Mar 26; 360(13): 1283–97.
Cite This Article
  • APA Style

    Zewde, W. Z., Mamo, A. G., Afework, H. Y., Desalegn, M. M., Hayle, E. B., et al. (2025). The Effect of Multiple Glycemic Parameters on Mortality and Clinical Outcomes in Critically Ill Patients in Intensive Care Unit. International Journal of Diabetes and Endocrinology, 10(2), 26-36. https://doi.org/10.11648/j.ijde.20251002.11

    Copy | Download

    ACS Style

    Zewde, W. Z.; Mamo, A. G.; Afework, H. Y.; Desalegn, M. M.; Hayle, E. B., et al. The Effect of Multiple Glycemic Parameters on Mortality and Clinical Outcomes in Critically Ill Patients in Intensive Care Unit. Int. J. Diabetes Endocrinol. 2025, 10(2), 26-36. doi: 10.11648/j.ijde.20251002.11

    Copy | Download

    AMA Style

    Zewde WZ, Mamo AG, Afework HY, Desalegn MM, Hayle EB, et al. The Effect of Multiple Glycemic Parameters on Mortality and Clinical Outcomes in Critically Ill Patients in Intensive Care Unit. Int J Diabetes Endocrinol. 2025;10(2):26-36. doi: 10.11648/j.ijde.20251002.11

    Copy | Download

  • @article{10.11648/j.ijde.20251002.11,
      author = {Wasihun Zerfu Zewde and Amare Gulilat Mamo and Helina Yohannes Afework and Mahlet Mitiku Desalegn and Ermiyas Berehanu Hayle and Zewdu Abadi Tsegay and Mehariw Wondim Netsere and Amir Muhidin Abrahim and Yeabtsega Amlaku Asres},
      title = {The Effect of Multiple Glycemic Parameters on Mortality and Clinical Outcomes in Critically Ill Patients in Intensive Care Unit
    },
      journal = {International Journal of Diabetes and Endocrinology},
      volume = {10},
      number = {2},
      pages = {26-36},
      doi = {10.11648/j.ijde.20251002.11},
      url = {https://doi.org/10.11648/j.ijde.20251002.11},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijde.20251002.11},
      abstract = {Background: Dysglycemia is frequently encountered in the ICU and it includes hyperglycemia, hypoglycemia and glycemic variability which are associated with increased rate of mortality and morbidity. Hyperglycemia is the most frequent among the components of dysglycemia and its prevalence is 40-90%. The prevalence and outcome of multiple glycemic parameters in the ICU has not been described in Ethiopia. Objectives: The aim of the study is to describe the effect of multiple glycemic parameters on intensive care unit mortality and clinical outcomes in selected tertiary hospitals. Methods: An institution based cross-sectional study was conducted by using systematic random sampling. Data was collected from patient cards and was entered using Epi Info 7.2. Data analysis was done using SPSS 27.0. Descriptive statistics was used to summarize the data. Associations between variables were measured with chi square and Mann Whitney U test. Multivariable logistic regression was used to identify predictors of mortality and test the association of multiple glycemic parameters and mortality. Odds ratios with 95% confidence intervals were calculated, and a p-value <0.05 was considered to declare significance Result: The study included 392 patient records, with a median age of 38 years [IQR 28 – 56]. About 53% of patients were females. The prevalence of hyperglycemia, hypoglycemia and high glycemic variability was 90.3%, 16.3% and 19.4% respectively. Hypoglycemia was significantly associated with mortality (AOR 2.98, p < .05). Patients with hyperglycemia and hypoglycemia had significantly longer lengths of stay and durations of mechanical ventilation. High glycemic variability was not significantly associated with mortality, length of stay or duration of mechanical ventilation. Conclusion: Dysglycemia is very prevalent among patients admitted in the ICU and hypoglycemia may be associated with ICU mortality and adverse clinical outcomes.
    },
     year = {2025}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - The Effect of Multiple Glycemic Parameters on Mortality and Clinical Outcomes in Critically Ill Patients in Intensive Care Unit
    
    AU  - Wasihun Zerfu Zewde
    AU  - Amare Gulilat Mamo
    AU  - Helina Yohannes Afework
    AU  - Mahlet Mitiku Desalegn
    AU  - Ermiyas Berehanu Hayle
    AU  - Zewdu Abadi Tsegay
    AU  - Mehariw Wondim Netsere
    AU  - Amir Muhidin Abrahim
    AU  - Yeabtsega Amlaku Asres
    Y1  - 2025/04/22
    PY  - 2025
    N1  - https://doi.org/10.11648/j.ijde.20251002.11
    DO  - 10.11648/j.ijde.20251002.11
    T2  - International Journal of Diabetes and Endocrinology
    JF  - International Journal of Diabetes and Endocrinology
    JO  - International Journal of Diabetes and Endocrinology
    SP  - 26
    EP  - 36
    PB  - Science Publishing Group
    SN  - 2640-1371
    UR  - https://doi.org/10.11648/j.ijde.20251002.11
    AB  - Background: Dysglycemia is frequently encountered in the ICU and it includes hyperglycemia, hypoglycemia and glycemic variability which are associated with increased rate of mortality and morbidity. Hyperglycemia is the most frequent among the components of dysglycemia and its prevalence is 40-90%. The prevalence and outcome of multiple glycemic parameters in the ICU has not been described in Ethiopia. Objectives: The aim of the study is to describe the effect of multiple glycemic parameters on intensive care unit mortality and clinical outcomes in selected tertiary hospitals. Methods: An institution based cross-sectional study was conducted by using systematic random sampling. Data was collected from patient cards and was entered using Epi Info 7.2. Data analysis was done using SPSS 27.0. Descriptive statistics was used to summarize the data. Associations between variables were measured with chi square and Mann Whitney U test. Multivariable logistic regression was used to identify predictors of mortality and test the association of multiple glycemic parameters and mortality. Odds ratios with 95% confidence intervals were calculated, and a p-value <0.05 was considered to declare significance Result: The study included 392 patient records, with a median age of 38 years [IQR 28 – 56]. About 53% of patients were females. The prevalence of hyperglycemia, hypoglycemia and high glycemic variability was 90.3%, 16.3% and 19.4% respectively. Hypoglycemia was significantly associated with mortality (AOR 2.98, p < .05). Patients with hyperglycemia and hypoglycemia had significantly longer lengths of stay and durations of mechanical ventilation. High glycemic variability was not significantly associated with mortality, length of stay or duration of mechanical ventilation. Conclusion: Dysglycemia is very prevalent among patients admitted in the ICU and hypoglycemia may be associated with ICU mortality and adverse clinical outcomes.
    
    VL  - 10
    IS  - 2
    ER  - 

    Copy | Download

Author Information